MargaretMacyMD

Clinical Trials

• Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients Start of enrollment: 2009 Aug 01

  Completed

  Phase 2

• The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors Start of enrollment: 2010 Jun 28

  Terminated

  Not Applicable

• Neuroblastoma Biology Study Start of enrollment: 2011 Jul 01

  Recruiting

• Expanded Access Protocol Using 131I-MIBG

  Available

• Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04

  Active, not recruiting

  Phase 1

• N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16

  Active, not recruiting

  Phase 1

• 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01

  Completed

  Phase 2

• Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma Start of enrollment: 2015 Oct 08

  Active, not recruiting

  Phase 1

• SF1126 for Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2015 Jul 09

  Terminated

  Phase 1

• The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study Start of enrollment: 2015 Oct 01

  Active, not recruiting

• A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2015 Oct 21

  Completed

  Phase 1

• A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Start of enrollment: 2016 Jan 07

  Completed

  Phase 1

• Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Start of enrollment: 2016 Feb 01

  Completed

  Phase 1

• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Start of enrollment: 2016 May 03

  Active, not recruiting

  Phase 1, Phase 2

• A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Start of enrollment: 2016 Mar 01

  Completed

  Phase 1, Phase 2

• Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Start of enrollment: 2015 Dec 01

  Withdrawn

  Phase 1

• Neuroblastoma Precision Trial Start of enrollment: 2016 Aug 22

  Active, not recruiting

• NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Start of enrollment: 2017 Sep 05

  Active, not recruiting

  Phase 1

• A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects Start of enrollment: 2019 Oct 21

  Recruiting

  Phase 2

• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08

  Active, not recruiting

  Phase 2

• Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2019 May 17

  Completed

  Phase 1

• A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Start of enrollment: 2020 Mar 12

  Recruiting

  Phase 1, Phase 2

• CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Start of enrollment: 2020 Jan 22

  Active, not recruiting

  Phase 1, Phase 2

• CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Start of enrollment: 2020 Mar 04

  Terminated

  Phase 1, Phase 2

• MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12

  Active, not recruiting

  Phase 1

  Roles: Contact

• NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Start of enrollment: 2024 Jul 01

  Not yet recruiting

  Phase 2

  Roles: Contact

• Join now to see all